The Merck Accelerator Program 2019

MerckThe Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Satellites events in Africa, startups can find their perfect fit and connect to the global network for collaboration. Are you ready to partner with Merck?

Applications for the HQ Program are open! From July until the end of September Merck will be looking for startups to join the Accelerator Program in Darmstadt. Come to the headquarters to connect with worldwide decision-makers and win Merck as your business partner. Take your chance to extend your stay in the Innovation Hub in China and succeed in accessing the Chinese market.

What are the key benefits of Merck Accelerator?

  • Partnership: Merck Accelerator is looking for strong business alliances and want to partner up with promising startups to build sustainable and successful business relationships.
  • Mentoring: Receive mentoring from members of Senior Management and Merck global network of over 50,000 experts. Dive deep into mentoring sessions and workshops.
  • Curriculum: Benefit from tailored coaching sessions and workshops provided by the Innovator Academy.
  • Funding: Kick off your startup project with seed funding of up to €50,000 and access Merck Accelerator investor network.
  • Access to the Chinese Market: Selected startups will also have the chance to extend their stay by joining our China Innovation Hub
  • Community: Team up with others facing the same challenges and build lifelong relationships.

A bustling city in the heart of Germany

The Rhine-Main region is a culturally and economically vibrant region in Hesse, Germany. It is home to the metropolises of Frankfurt and the state capitals of Wiesbaden and Mainz. Darmstadt is a city well-accustomed to witnessing big developments in science and high-tech. The city is home to several renowned scientific and technological institutions, as well as many great discoveries in chemistry and physics. Darmstadt has also been named "Digital City" and "City of the Future" in recognition of its status as Germany's most promising digital location of the future.

Are you ready to access the Chinese market?

Following the HQ program, selected startups could qualify to participate in the Merck Accelerator extension in China. They will get guidance to access the Chinese Market, as well as insights on the local regulatory affairs and customers-base. The HQ Accelerator Program is therefore complemented by a tailored Program in the China Innovation hub in Shanghai in which the startups will be able to choose curriculum and mentoring subjects, as well as trainings for localizing their business model in China and developing partnership strategies.

Start your journey in the Merck headquarter in Darmstadt, Germany and use your chance to also get access to the Chinese market via Merck.

When & Where

The HQ Accelerator program application phase is running from July until September 2018.
The HQ Accelerator intake will take place from January until April 2019 (3 months at the Innovation Center).

Are you a startup operating in the fields of healthcare, performance materials, life sciences, and other related business fields?

Then apply now via the web link below:
https://www.f6s.com/acceleratorprogram2019

Application submission deadline: September 30th 2018

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

BioMotiv and Bristol-Myers Squibb announce the lau…

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from ...

CEPI and GSK announce collaboration to strengthen …

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV...

Sandoz completes acquisition of Aspen's Japanese o…

Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen ...

Roche reports very strong results in 2019

In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business...

Sanofi brain-penetrant BTK inhibitor meets primary…

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieve...

Sanofi completes acquisition of Synthorx, Inc.

Sanofi announced the successful completion of its acquisition of Synthorx, Inc. ("Synthorx") for $68 per share in cash. "The acquisition of Synthorx perfectly aligns w...

Merck donates one billionth praziquantel tablet

Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment ...

WHO, China leaders discuss next steps in battle ag…

The Director-General of the World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus, met President Xi Jinping of the People's Republic of China in Beijing. They sh...

FDA approves first drug for treatment of peanut al…

Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, tha...

Poliovirus therapy shows potential as cancer vacci…

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for...

Bayer and Nuvisan create new research unit in Berl…

Bayer AG today announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an internationa...

AstraZeneca divests rights to established hyperten…

AstraZeneca has agreed to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Ze...